Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SBM-04
- Development stage
- Preclinical
- Lead developer
- Shilpa Biologicals
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
SBM-04 is a biosimilar Fc fusion protein currently in preclinical development by Shilpa Biologicals for the treatment of rheumatological conditions. It is a biosimilar candidate for **abatacept** (Orencia). The molecule is designed to function as a selective T-cell costimulation modulator, consisting of the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) fused to a modified Fc portion of human immunoglobulin G1 (IgG1). By binding to CD80 and CD86 on antigen-presenting cells, it inhibits the costimulatory signal required for T-cell activation, thereby reducing the inflammatory response associated with autoimmune diseases such as rheumatoid arthritis.
- Other names
- FC Fusion Protein Biosimilar
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)CD80 (T-lymphocyte activation antigen CD80)CD86 (T-lymphocyte activation antigen CD86)FCGRT (Neonatal crystallizable fragment receptor)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)
Beyond the preview
Go deeper on SBM-04.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SBM-04.